# Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)

> **NCT07120698** · PHASE2 · RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 115 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)
- MRD
- II-IIIB Stages
- Adjuvant Immunotherapy

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT07120698
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-05
- **Primary completion:** 2029-06-26
- **Final completion:** 2029-07-26
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07120698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07120698, "Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT07120698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*